Management of Acute Pancreatitis

Diagnosis and Assessment

• The diagnosis of moderately severe acute pancreatitis is based on elevated pancreatic enzymes, leukocytosis suggesting systemic inflammatory response, CT evidence of peripancreatic fluid, and hemodynamic stability on supportive care 1
• Elevated pancreatic enzymes, such as amylase and lipase, are indicative of acute pancreatitis 1
• Leukocytosis, or an elevated white blood cell count, suggests a systemic inflammatory response 1
• CT evidence of peripancreatic fluid is a key diagnostic criterion for acute pancreatitis 1

Management

• The American College of Surgeons recommends IV fluid resuscitation to maintain hydration in patients with acute pancreatitis 1
• The World Journal of Emergency Surgery suggests that analgesics, such as morphine or hydromorphone, be used for pain control in patients with severe acute pancreatitis 2, 3
• Enteral nutrition, such as oral, NG, or NJ feeding, is recommended if tolerated 1
• Monitoring of hematocrit, BUN, creatinine, and continuous vital signs is crucial in managing acute pancreatitis 1
• Procalcitonin is the most sensitive test for detecting pancreatic infection, and antibiotics should only be given for confirmed infections 1

Treatment

• Prophylactic antibiotics are not recommended for acute pancreatitis and do not decrease mortality or morbidity 1, 2
• The World Journal of Emergency Surgery recommends that antibiotics be reserved only for treating infected severe acute pancreatitis, not prophylaxis 1
• Surgery is not indicated for sterile acute pancreatitis, but may be necessary for infected pancreatic necrosis or pancreatic abscess 1
• The American College of Surgeons recommends that surgical intervention be delayed 2-3 weeks to allow demarcation of necrotic tissue, if necessary 1

Pain Management

• Hydromorphone is preferred over morphine in non-intubated patients for severe pain management 2, 3
• Laxatives must be routinely prescribed to prevent opioid-induced constipation 3
• Metoclopramide may be used for opioid-related nausea/vomiting 3

Management of Acute Pancreatitis

Clinical Management

• The past clinical emphasis on "gut rest" to decrease pancreatic stimulation has been revised, as per the Clinical Nutrition guidelines 4
• Peripancreatic fluid on CT, which is common (occurs in 30-50% of severe cases), resolves spontaneously in more than half of the cases, according to Gut 5
• Daily reassessment for development ofogle of complications including clinical, biochemical, and radiological evaluation is necessary, as recommended by Gut 5
• Early enteral feeding is safe and beneficial when tolerated, as stated in Clinical Nutrition 4

Surgical Intervention

• Surgical intervention should be limited to patients with infected pancreatic necrosis or pancreatic abscess confirmed by radiologic evidence of gas or fine needle aspirate results, with operative necrosectomy and/or drainage delayed at least 2-3 weeks to allow for demarcation of necrotic tissue, as per Gut 5

Pain Management in Acute Pancreatitis

Severity-Based Approach

• For mild acute pancreatitis (80% of cases), opioids on an as-needed basis with close monitoring on general wards suffice, as recommended by the Gut guideline society 6
• For severe acute pancreatitis (20% of cases, 95% of deaths), intensive monitoring in HDU/ITU settings is mandatory with continuous vital signs monitoring including oxygen saturation, as suggested by the Gut and World Journal of Emergency Surgery guideline societies 6, 7
• Regular arterial blood gas analysis to detect hypoxia and acidosis early is also recommended for severe acute pancreatitis, according to the Gut guideline society 6

Surgical Management Timing and Strategy in Acute Pancreatitis

Timing of Surgical Intervention

Step‑up Approach Prior to Surgery

Acute Pancreatitis: Evidence‑Based Diagnosis, Severity Assessment, and Management

Diagnosis

• Acute pancreatitis is diagnosed when any two of the following are present: (1) epigastric pain radiating to the back, (2) serum lipase or amylase ≥ 3 × upper limit of normal, or (3) characteristic findings on contrast‑enhanced CT or MRI. 9

Initial Laboratory Workup

• At admission obtain serum amylase or lipase, triglycerides, calcium, liver panel (bilirubin, AST, ALT, alkaline phosphatase), complete blood count, electrolytes, BUN, creatinine, and hematocrit. 10
• Measure C‑reactive protein 48 h after symptom onset; values > 150 mg/L predict severe disease. 10
• Serial monitoring of hematocrit, BUN, creatinine, and lactate serves as a bedside assessment of tissue perfusion. 11

Severity Stratification

• Patients with persistent organ failure (cardiovascular, respiratory, or renal) should be admitted directly to an intensive‑care unit. 9
• Persistent organ failure combined with infected pancreatic necrosis confers the highest mortality risk. 9
• Contrast‑enhanced CT is reserved for cases with an unclear diagnosis or lack of clinical improvement within 72 h of presentation. 10

Fluid Resuscitation

• Initiate aggressive intravenous isotonic crystalloid therapy (Ringer’s lactate preferred) as early as possible, with the greatest benefit occurring within the first 12–24 h. 11
• Provide vigorous fluid resuscitation to all patients unless significant cardiovascular or renal comorbidities contraindicate it. 10
• Guide fluid administration by frequent hemodynamic reassessment; avoid fluid overload because of its detrimental effects. 11
• Ongoing assessment of hematocrit, BUN, creatinine, and lactate helps gauge volemic status and tissue perfusion. 11

Nutrition Management

• In mild pancreatitis without nausea or vomiting, start early oral feeding as soon as tolerated.
• In severe pancreatitis, initiate enteral nutrition (naso‑jejunal tube with elemental or semi‑elemental formula) within 48 h rather than keeping the patient NPO. 10
• Total parenteral nutrition is reserved for patients who cannot tolerate enteral feeding. 10
• Provide nutritional support when patients are expected to remain NPO for > 7 days. 10

Antibiotic Therapy

• For confirmed infected pancreatic necrosis, use agents with good pancreatic tissue penetration such as carbapenems or piperacillin‑tazobactam. 11
• Quinolones should be avoided because of high worldwide resistance rates, unless the patient has a β‑lactam allergy. 11

Gallstone‑Related Pancreatitis

• Perform abdominal ultrasonography on admission to detect gallstones or common bile duct stones. 10
• In patients with concurrent acute cholangitis, conduct urgent ERCP within 24 h. 10
• When there is a high suspicion of a persistent common bile duct stone (visible stone on imaging, persistent ductal dilation, or jaundice), perform early ERCP within 72 h. 10
• Cholecystectomy should be performed during the same hospital admission when feasible; if not, schedule it within 2–4 weeks after discharge. 10

Evaluation of Unexplained Pancreatitis

• For patients > 40 years of age, obtain CT or endoscopic ultrasound (EUS) to screen for underlying pancreatic malignancy. 10
• In patients < 40 years with a single episode, extensive imaging is generally unnecessary. 10
• For recurrent episodes, evaluate with EUS (preferred) and/or ERCP to identify occult causes. 10

Management of Pancreatic Necrosis

• Sterile necrosis typically does not require therapeutic intervention. 10

Monitoring and Complications

• Patients with organ dysfunction require continuous vital‑sign monitoring, including oxygen saturation, in a high‑dependency or intensive‑care setting. 11
• In severe disease, actively monitor for abdominal compartment syndrome. 11

Emergency Department Management of Acute Pancreatitis

Diagnosis

• Lipase measurement is preferred over amylase for confirming acute pancreatitis when the assay is available, because lipase has higher diagnostic accuracy. 12

Severity Stratification

• The World Society of Emergency Surgery (WSES) recommends applying the Revised Atlanta Classification or the Determinant‑based Classification within the first 24 h to categorize disease severity. 13
• Early clinical impression of severity, a body‑mass index > 30 kg/m², an APACHE II score > 8, and the presence of a pleural effusion on chest radiograph are independent predictors of severe disease and should be assessed on presentation. [12][14][15][16]
• At 48 h, a Glasgow score ≥ 3, a C‑reactive protein level > 150 mg/L, or persistent organ failure for ≥48 h identify patients with ongoing severe pancreatitis and guide escalation of care. [12][14]
• Patients who develop persistent organ failure (cardiovascular, respiratory, or renal) are classified as having severe acute pancreatitis and should be admitted to an intensive‑care unit. 13
• The combination of persistent organ failure and infected pancreatic necrosis confers the highest mortality risk and mandates aggressive intensive‑care support. 13

Antibiotic Policy

• Routine prophylactic antibiotics are not recommended for acute pancreatitis; high‑quality randomized trials have shown no reduction in infected necrosis or mortality. [12][14]13
• If antibiotics are used contrary to guideline recommendations, the duration should not exceed 14 days. [12][14]

Imaging Strategy

• Contrast‑enhanced CT should be reserved for patients in whom imaging will change management; routine early CT within the first week is discouraged unless specific decisions (e.g., necrosis assessment) require it. [17][15]18
• Indications for CT after admission include persistent organ failure, signs of sepsis or clinical deterioration between days 6–10, and lack of clinical improvement within 72 h. [12][14]
• When CT is performed, the Balthazar CT severity index should be used to grade pancreatic and peripancreatic inflammation. [17][15]18
• A spiral or multislice CT with intravenous non‑ionic contrast (approximately 100 mL at 3 mL/s) is required for adequate assessment; non‑contrast CT provides suboptimal information and should be avoided. [17][15]18

Nutritional Support

• Enteral nutrition is the preferred route when oral intake is not possible; it should be initiated within 48 h for severe pancreatitis. [12][14]
• Nasogastric tube feeding is effective in about 80 % of patients who can tolerate enteral nutrition. [12][14]
• Total parenteral nutrition is reserved for patients who cannot receive enteral feeding.

Management of Gallstone‑Related Pancreatitis

• Early endoscopic retrograde cholangiopancreatography (ERCP) within 72 h is indicated for patients with suspected or confirmed gallstone etiology who have predicted or actual severe pancreatitis, cholangitis, jaundice, or a dilated common bile duct. [12][14]19
• All patients undergoing early ERCP for severe gallstone pancreatitis should receive endoscopic sphincterotomy regardless of stone detection. [12][14]
• Definitive gallstone management (cholecystectomy) should be performed during the same hospital admission unless a clear plan for surgery within two weeks exists. [12][14]

Disposition and Referral

• Each hospital receiving acute pancreatitis admissions should designate a single clinical team responsible for the care of all such patients. [12][14]
• Patients with severe acute pancreatitis require management in a high‑dependency unit or intensive‑care unit with full monitoring and support. [12][14]20
• Referral to a specialist centre is mandatory for patients with extensive necrotizing pancreatitis or complications that may need intensive care, interventional radiology, advanced endoscopy, or surgery. [12][14]

Critical Pitfalls to Avoid

• Do not delay aggressive fluid resuscitation; early goal‑directed volume replacement within the first 12–24 h is essential. 13
• Do not administer prophylactic antibiotics routinely, as they have not demonstrated benefit in high‑quality trials. [12][14]
• Do not perform routine early CT within the first week unless specific management decisions depend on the imaging findings. [17][15]18
• Do not keep patients nil‑by‑mouth routinely; early oral or enteral feeding reduces the need for invasive interventions. [12][14]

Evidence‑Based Recommendations for Antibiotics, Monitoring, and Immunotherapy‑Related Pancreatitis

Antibiotic Use in Acute Pancreatitis

• Reserve antimicrobial therapy only for confirmed infected pancreatic necrosis; prophylactic antibiotics are not recommended. Preferred agents are carbapenems or piperacillin‑tazobactam because of superior pancreatic tissue penetration. 21

Monitoring for Complications

• Implement systematic surveillance for severe complications:
  
  • Infected necrosis – use procalcitonin as the most sensitive laboratory marker.
  • Organ failure – assess with the Sequential Organ Failure Assessment (SOFA) score.
  • Abdominal compartment syndrome – monitor intra‑abdominal pressure and clinical signs. 21

Management of Immune Checkpoint Inhibitor–Induced Pancreatitis

• For moderate‑severity pancreatitis caused by immune checkpoint inhibitors, hold the immunotherapy and initiate high‑dose corticosteroids with a planned six‑week taper. In cases of severe pancreatitis, permanently discontinue the immunotherapy agent. 22